Kymera Therapeutics (KYMR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kymera Therapeutics

NasdaqGM•Healthcare•Biotechnology

$110.85-1.78(-0.02%)After hours

Market Cap

$12.72B

P/S

124.4x

P/B

7.9x

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How this company scores

AverageMetricSide Score: 41/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability6/25

Growth14/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 124.4x5y range 17.3x – 179.4x

Currently above its 20-quarter median.

P/B · 7.9x5y range 2.1x – 7.9x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $12.72B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $102.24M
Q. Revenue: $0
TTM EBITDA: $-392.55M
TTM Op. Income: $-404.89M
Q. Op. Income: $-147.23M
TTM Net Income: $-349.43M
Q. Net Income: $-132.00M
EPS: $-1.32
Shares Out.: $100.10M

$102.24M in TTM revenue grew 133.8% YoY, reaching $0 last quarter. TTM EBITDA of $-392.55M and TTM operating income of $-404.89M show growth is flowing through to the bottom line. However, net income is negative at $349.43M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 134% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -14723200000.0%
Net Margin: -13199900000.0%

Op. margin of -14723200000.0% is down 14723196652.6% YoY — costs are rising relative to revenue. Net margin at -13199900000.0% Over the past year, operating margin is down 439845176% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 124.4x
P/B Ratio: 7.9x

P/S of 124.4x and P/B of 7.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.77B
Cash: $373.37M
Long-Term Debt: N/A
Book Value: $1.61B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-77.91M
TTM Free Cash Flow: $-288.89M
FCF Margin: -282.6%
FCF / Net Income: 0.8

TTM FCF of $-288.89M on $-77.91M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 25% — a weakening trend.